Immune Regulation News Volume 13.32 | Aug 27 2021

    By
    Justin.choi
    -
    0
    104







    2021-08-27 | IRN 13.32


    Immune Regulation News by STEMCELL Technologies
    Vol. 13.32 – 27 August, 2021
    TOP STORY

    Anti-PD-1/L1 Lead-In before MAPK Inhibitor Combination Maximizes Antitumor Immunity and Efficacy

    Researchers compared the efficacies of sequential and/or combinatorial regimens in subcutaneous murine models of melanoma driven by BrafV600, Nras, or Nf1 mutations as well as colorectal and pancreatic carcinoma driven by KrasG12C.
    [Cancer Cell]

    Full ArticleGraphical Abstract
    SepMateâ„¢ PBMC Isolation
    PUBLICATIONSRanked by the impact factor of the journal

    Discrete Tissue Microenvironments Instruct Diversity in Resident Memory T Cell Function and Plasticity

    Investigators analyzed tissue-resident memory T cell (TRM) heterogeneity between organs and found that the different environments in which these cells differentiate dictated TRM cell function, durability and malleability.
    [Nature Immunology]

    Abstract

    Regulatory T Cells Function in Established Systemic Inflammation and Reverse Fatal Autoimmunity

    By reinstating Foxp3 protein expression and suppressor function in cells expressing a reversible Foxp3 null allele in severely diseased mice, researchers found that the resulting single pool of rescued Treg cells normalized immune activation, quelled severe tissue inflammation, reversed fatal autoimmune disease and provided long-term protection against them.
    [Nature Immunology]

    Abstract

    Immunotherapy Combinations Overcome Resistance to Bispecific T Cell Engager Treatment in T Cell–Cold Solid Tumors

    Using an immunocompetent mouse model expressing a humanized CD3ε chain and bispecific T cell engager (BiTE) molecules directed against mouse CD19, mouse CLDN18.2, or human EPCAM antigens, researchers investigated the pharmacokinetic and pharmacodynamic parameters and immune correlates associated with BiTE efficacy across multiple syngeneic solid-tumor models.
    [Science Translational Medicine]

    Abstract

    Alveolar Macrophages Rely on GM-CSF from Alveolar Epithelial Type 2 Cells before and after Birth

    Investigators developed new transgenic mice to profile pulmonary GM-CSF expression, which they detected in both immune cells, including group 2 innate lymphoid cells and γδ T cells, as well as AT2s.
    [Journal of Experimental Medicine]

    Abstract

    Pro-Inflammatory T Helper 17 Directly Harms Oligodendrocytes in Neuroinflammation

    The authors visualized central nervous system inflammatory processes in models of multiple sclerosis (MS) live in vivo and in MS brains and discovered that central nervous system-infiltrating T helper 17 cells form prolonged stable contact with oligodendrocytes.
    [Proceedings of the National Academy of Sciences of the United States of America]

    Full Article

    LRRK2 Plays Essential Roles in Maintaining Lung Homeostasis and Preventing the Development of Pulmonary Fibrosis

    Researchers showed that leucine-rich repeat kinase 2 (LRRK2) expression was clearly reduced in mammalian fibrotic lungs, and LRRK2-deficient mice exhibited aggravated bleomycin-induced pulmonary fibrosis.
    [Proceedings of the National Academy of Sciences of the United States of America]

    Abstract

    Alternative Activation of Macrophages through Interleukin-13-Loaded Extra-Large-Pore Mesoporous Silica Nanoparticles Suppresses Experimental Autoimmune Encephalomyelitis

    The authors showed that interleukin-13 packaged in extra-large-pore mesoporous silica nanoparticles was protected from degradation and directs the alternative activation of macrophages both in vitro and in vivo.
    [ACS Biomaterials Science & Engineering]

    AbstractGraphical Abstract

    Aberrant Gene Expression of Selenoproteins in Chicken Spleen Lymphocytes Induced by Mercuric Chloride

    Investigators established cytotoxicity model of chicken spleen lymphocytes by HgCl2 exposure, the mRNA expression levels of 25 selenoproteins in spleen lymphocytes were analyzed by real-time quantitative PCR, and the gene expression pattern of selenoproteins was revealed by principal component analysis.
    [Biological Trace Element Research]

    Abstract
    Maximize Post-Thaw Cell Recovery with cGMP-Manufactured Cryopreservation Media. Learn More.
    REVIEWS

    The Promise of the Gut Microbiome as Part of Individualized Treatment Strategies

    Scientists discuss six broad disease groups: infectious disease, cancer, metabolic disease, cardiovascular disease, autoimmune or inflammatory disease, and allergic and atopic diseases.
    [Nature Reviews Gastroenterology & Hepatology]

    Abstract

    Cutting Both Ways: The Innate Immune Response to Oncolytic Virotherapy

    The authors discuss the importance of oncolytic viruses-based combination therapies in optimizing antiviral and antitumor innate immune responses stimulated by virotherapy toward tumor eradication, and how these processes vary depending on the tumor and oncolytic viruses in question.
    [Cancer Gene Therapy]

    Abstract
    INDUSTRY AND POLICY NEWS

    Bolt Biotherapeutics and Innovent Biologics Announce Collaboration to Develop Three New Oncology Boltbodyâ„¢ ISAC Programs

    Bolt Biotherapeutics, Inc. and Innovent Biologics, Inc. announced a drug research and development collaboration to develop three new anti-cancer therapeutic immune-stimulating antibody conjugate candidates.
    [Bolt Biotherapeutics, Inc.]

    Press Release

    ImmunoBrain Checkpoint Awarded $5 Million US NIA Grant for Phase Ib Alzheimer’s Disease Proof-of-Mechanism Study of Anti-PD-L1 IBC-Ab002

    ImmunoBrain Checkpoint, Inc. announced that the National Institute on Aging (NIA) of the US National Institutes of Health has awarded the company a grant totaling $5 million over three years to support a first-in-human clinical study of IBC-Ab002, for the treatment of Alzheimer’s disease.
    [ImmunoBrain Checkpoint, Inc. (GlobeNewswire, Inc.)]

    Press Release

    Bolt Biotherapeutics and Innovent Biologics Announce Collaboration to Develop Three New Oncology Boltbodyâ„¢ ISAC Programs

    Bolt Biotherapeutics, Inc. and Innovent Biologics, Inc. announced a drug research and development collaboration to develop three new anti-cancer therapeutic immune-stimulating antibody conjugate candidates.
    [Bolt Biotherapeutics, Inc.]

    Press Release
    FEATURED EVENT

    Immuno UK

    October 13 – 14, 2021
    London, England, United Kingdom

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Fellow – Immune Homeostasis of the Intestinal Tract

    University of North Dakota – Grand Forks, North Dakota, United States

    Research Assistant – Chronic Inflammatory and Degenerative Diseases

    University of Oxford – Oxford, England, United Kingdom

    Senior Scientist – Immuno-Oncology

    Epitopea – Cambridge, England, United Kingdom

    Research Fellow – Cancer Immunology and Stem Cells Research

    Dana-Farber Cancer Institute- Boston, Massachusetts, United States

    Assistant/Associate/Full Professor Tenure-Track – Aging and Inflammation

    Medical College of Georgia, Augusta University – Augusta, Georgia, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Immune Regulation News Twitter